PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17156920-0	2007	Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.	Morphine	62-70	catechol-O-methyltransferase	Homo sapiens	98-102	
17156920-4	2007	We assessed joint effects of the OPRM1 and COMT genes in predicting morphine dose for cancer pain relief.	Morphine	68-76	catechol-O-methyltransferase	Homo sapiens	43-47	
17156920-6	2007	Results showed significant variation in morphine dose requirement by genotype groups: carriers of COMT Val/Val and Val/Met genotype required 63% and 23%, respectively, higher morphine dose compared to carriers of Met/Met genotype (p=0.02).	Morphine	40-48	catechol-O-methyltransferase	Homo sapiens	98-102	
17156920-6	2007	Results showed significant variation in morphine dose requirement by genotype groups: carriers of COMT Val/Val and Val/Met genotype required 63% and 23%, respectively, higher morphine dose compared to carriers of Met/Met genotype (p=0.02).	Morphine	175-183	catechol-O-methyltransferase	Homo sapiens	98-102	
17156920-8	2007	When we explored for joint effects, we found that carriers of the OPRM1 AA and COMT Met/Met genotype required the lowest morphine dose to achieve pain relief (87 mg/24 h; 95%CI=57,116) and those with neither Met/Met nor AA genotype needed the highest morphine dose (147 mg/24 h; 95%CI=100,180).	Morphine	121-129	catechol-O-methyltransferase	Homo sapiens	79-83